These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 10631622)

  • 1. Repaglinide in type 2 diabetes: a 24-week, fixed-dose efficacy and safety study.
    Jovanovic L; Dailey G; Huang WC; Strange P; Goldstein BJ
    J Clin Pharmacol; 2000 Jan; 40(1):49-57. PubMed ID: 10631622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients.
    Damsbo P; Clauson P; Marbury TC; Windfeld K
    Diabetes Care; 1999 May; 22(5):789-94. PubMed ID: 10332683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes.
    Goldberg RB; Einhorn D; Lucas CP; Rendell MS; Damsbo P; Huang WC; Strange P; Brodows RG
    Diabetes Care; 1998 Nov; 21(11):1897-903. PubMed ID: 9802740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flexible meal-related dosing with repaglinide facilitates glycemic control in therapy-naive type 2 diabetes.
    Moses RG; Gomis R; Frandsen KB; Schlienger JL; Dedov I
    Diabetes Care; 2001 Jan; 24(1):11-5. PubMed ID: 11194214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics, pharmacodynamics, and dose-response relationship of repaglinide in type 2 diabetes.
    Strange P; Schwartz SL; Graf RJ; Polvino W; Weston I; Marbury TC; Huang WC; Goldberg RB
    Diabetes Technol Ther; 1999; 1(3):247-56. PubMed ID: 11475269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination therapy for type 2 diabetes: repaglinide plus rosiglitazone.
    Raskin P; McGill J; Saad MF; Cappleman JM; Kaye W; Khutoryansky N; Hale PM;
    Diabet Med; 2004 Apr; 21(4):329-35. PubMed ID: 15049934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function.
    Hasslacher C;
    Diabetes Care; 2003 Mar; 26(3):886-91. PubMed ID: 12610054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized study of repaglinide alone and in combination with metformin in Chinese subjects with type 2 diabetes naive to oral antidiabetes therapy.
    Wang W; Bu R; Su Q; Liu J; Ning G
    Expert Opin Pharmacother; 2011 Dec; 12(18):2791-9. PubMed ID: 21780853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repaglinide versus glyburide: a one-year comparison trial.
    Marbury T; Huang WC; Strange P; Lebovitz H
    Diabetes Res Clin Pract; 1999 Mar; 43(3):155-66. PubMed ID: 10369424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing insulin secretagogue therapy in patients with type 2 diabetes: a randomized double-blind study with repaglinide.
    Schmitz O; Lund S; Andersen PH; Jønler M; Pørksen N
    Diabetes Care; 2002 Feb; 25(2):342-6. PubMed ID: 11815507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Dutch and German Repaglinide Study Group.
    Wolffenbuttel BH; Landgraf R
    Diabetes Care; 1999 Mar; 22(3):463-7. PubMed ID: 10097930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repaglinide: a short acting insulin secretagogue for postprandial hyperglycaemia.
    Ambavane V; Patil R; Ainapure SS
    J Postgrad Med; 2002; 48(3):246-8. PubMed ID: 12432213
    [No Abstract]   [Full Text] [Related]  

  • 14. Twice-daily and three-times-daily dosing of a repaglinide/metformin fixed-dose combination tablet provide similar glycaemic control.
    Raskin P; Lewin A; Reinhardt R; Lyness W;
    Diabetes Obes Metab; 2009 Oct; 11(10):947-52. PubMed ID: 19531054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose titration of repaglinide in patients with inadequately controlled type 2 diabetes.
    Kølendorf K; Eriksson J; Birkeland KI; Kjellström T; Hreidarsson AB
    Diabetes Res Clin Pract; 2004 Apr; 64(1):33-40. PubMed ID: 15036825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased prandial insulin secretion after administration of a single preprandial oral dose of repaglinide in patients with type 2 diabetes.
    Owens DR; Luzio SD; Ismail I; Bayer T
    Diabetes Care; 2000 Apr; 23(4):518-23. PubMed ID: 10857945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antidiabetic drug at every meal. Repaglinide is especially recommended for slender type 2 diabetic patients].
    Landgraf R
    MMW Fortschr Med; 2000 Jul; 142(28-29):29-30. PubMed ID: 10959157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repaglinide in combination therapy with metformin in Type 2 diabetes.
    Moses R
    Exp Clin Endocrinol Diabetes; 1999; 107 Suppl 4():S136-9. PubMed ID: 10522839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison between repaglinide and glipizide in Type 2 diabetes mellitus: a 1-year multicentre study.
    Madsbad S; Kilhovd B; Lager I; Mustajoki P; Dejgaard A;
    Diabet Med; 2001 May; 18(5):395-401. PubMed ID: 11472451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repaglinide treatment amplifies first-phase insulin secretion and high-frequency pulsatile insulin release in Type 2 diabetes.
    Hollingdal M; Sturis J; Gall MA; Damsbo P; Pincus S; Veldhuis JD; Pørksen N; Schmitz O; Juhl CB
    Diabet Med; 2005 Oct; 22(10):1408-13. PubMed ID: 16176204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.